Modular Medical Completes Pivot Patient Research Study with Thrivable
Modular Medical has completed a three-phase patient research study with Thrivable examining treatment burden, insulin pump adoption barriers and perceptions of its Pivot tubeless patch pump.
Modular Medical, Inc. (NASDAQ:MODD) has completed a three-phase market research study with Thrivable examining treatment burden, barriers to insulin pump adoption and perceptions of the company’s Pivot™ tubeless patch pump. More than 540 people with Type 1 and Type 2 diabetes participated in the research.
#Study examined treatment burden and pump adoption
The research included people using multiple daily injections (MDI) as well as participants who had moved to insulin pump therapy. The first phase involved over 230 participants who reviewed introductory Pivot materials and answered questions about treatment burden, adoption barriers and interest in a simplified patch pump.
A group of 20 participants then took part in 45-minute interviews. This group included people who had not used a pump, former pump users who had returned to injections and current pump users. The interviews explored participants’ decision-making, motivations and initial responses to Pivot.
The final phase surveyed more than 300 MDI users about product messaging, educational needs and factors that could encourage consideration of insulin pump therapy. The study also grouped respondents into high-, moderate- and low-burden categories based on four treatment-burden questions.
Approximately nine out of 10 MDI users said they would consider a simpler way to deliver insulin. Among participants classified as highly burdened, 82.8% said they would discuss Pivot with a healthcare provider. The corresponding figure for low-burden participants was 64.8%.
In the final phase, 48.5% of participants (N=303) expressed strong interest in Pivot. The company said the findings showed that treatment burden remains an issue for people managing diabetes with multiple daily injections.
Among pump-naïve participants, 41.8% identified the absence of a healthcare provider recommendation as their main reason for not adopting pump therapy.
Across more than 300 survey participants, lower cost was cited by 59.7% as an important factor in considering another insulin delivery method, while reduced effort was cited by 57.4%.
Among current pump users who had previously used injections, better glucose control was cited by 48.0% as a reason for switching. A further 44.0% said they had become tired of multiple daily injections.
#Information needs and Type 1 and Type 2 responses
Participants indicated that practical information about using a patch pump was important. The most frequently cited information need, reported by 54.1%, was how securely the device remains attached during daily activities.
The study reported different levels of interest between Type 1 and Type 2 respondents. Before detailed product messaging in the first phase, 85.1% of Type 2 respondents expressed strong interest, compared with 53.6% of Type 1 respondents. In the broader survey, 57.8% of Type 2 respondents and 38.9% of Type 1 respondents reported favourable perceptions of Pivot.
Jeb Besser, Modular Medical’s Chief Executive Officer, said the findings would inform patient engagement, educational initiatives and commercialisation planning as the company prepares for the full commercial launch of Pivot.
Modular Medical said the research was based on self-reported responses from a limited number of participants. The company cautioned that the results may not represent the broader patient population or predict actual patient adoption, healthcare provider recommendations or purchasing behaviour.
The company also identified risks related to executing the full commercial launch, market acceptance, manufacturing products at high volumes and general economic, industry or political conditions. Modular Medical describes Pivot as a tubeless patch pump designed for people requiring intensive insulin therapy.
More than 540 people with Type 1 and Type 2 diabetes took part in Modular Medical’s three-phase study with Thrivable.
Approximately nine out of 10 MDI users said they would consider a simpler insulin delivery option.
Among highly burdened participants, 82.8% said they would discuss Pivot with a healthcare provider.
Lower cost and reduced effort were cited by 59.7% and 57.4% of survey participants, respectively, as factors supporting consideration of another delivery method.
Modular Medical said the self-reported findings may not represent the broader patient population or predict actual adoption or purchasing behaviour.
Modular Medical announced the completion of a comprehensive market research study conducted with Thrivable on perceptions of its Pivot™ tubeless patch pump. The study involved more than 540 people with Type 1 and Type 2 diabetes and examined treatment burden, barriers to pump adoption and receptivity to simplified insulin delivery.
The announcement was made on November 9, 2026, and covers the completed multi-phase study conducted with Thrivable. The source does not provide separate start and end dates for the research.
More than 540 Type 1 and Type 2 diabetes participants took part in the study. It included multiple daily injection users and people who had transitioned to insulin pump therapy.
The first phase involved over 230 participants reviewing introductory Pivot™ materials and answering questions about treatment burden and pump adoption barriers. A further 20 participants took part in 45-minute interviews, while the final phase surveyed more than 300 multiple daily injection users about messaging, education and factors that could encourage consideration of insulin pump therapy.
Approximately nine out of 10 multiple daily injection users said they would consider a simpler insulin delivery option. Modular Medical said the responses indicated a desire for reduced treatment burden, although the company’s forward-looking statements note that the research was based on self-reported responses from a limited number of participants.
Among participants classified as highly burdened, 82.8% indicated they would discuss Pivot™ with their healthcare provider. The comparable figure for low-burden individuals was 64.8%.
Among pump-naïve participants, 41.8% cited the lack of a healthcare provider recommendation as their primary reason for not adopting pump therapy. Across more than 300 survey participants, lower cost, cited by 59.7%, and reduced effort, cited by 57.4%, were the two most important factors that would motivate consideration of an alternative insulin delivery method.
The leading reasons given by current pump users who had switched from injections were better glucose control, cited by 48.0%, and being tired of multiple daily injections, cited by 44.0%.
A top information need, cited by 54.1% of participants, was how securely the device stays attached during daily activities. The research also indicated that participants wanted practical, real-world information about patch pump use.
In the first phase, 85.1% of Type 2 respondents expressed strong interest compared with 53.6% of Type 1 respondents before detailed product messaging. In the broader survey, 57.8% of Type 2 respondents and 38.9% of Type 1 respondents indicated favourable perceptions of Pivot™.
Modular Medical is a commercial-stage medical device company focused on insulin delivery technologies intended to simplify diabetes management and increase access to insulin pump therapy. Its Pivot™ tubeless patch pump is designed to provide a user-friendly, flexible and accessible approach to insulin delivery for people requiring intensive insulin therapy.
Chief Executive Officer Jeb Besser said the insights from the collaboration with Thrivable will help guide Modular Medical’s patient engagement, educational initiatives and commercialisation planning as the company prepares to bring Pivot™ to people who may benefit from it. He also said the research identified treatment burden, cost and complexity as barriers to pump adoption.
Modular Medical identifies its shares as trading on NASDAQ under the ticker symbol MODD.
Modular Medical said the research may not be representative of the broader patient population or predictive of actual patient adoption, healthcare provider recommendations or purchasing behaviour because it was based on self-reported responses from a limited number of participants. The company also identified risks including its ability to execute the full commercial launch of Pivot™, market acceptance, manufacturing at high volumes and general economic, industry or political conditions.